Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 17, 2026.

Role of Copper on Mitochondrial Function and Metabolism

Lina M. Ruiz, Allan Libedinsky, Alvaro A. Elorza

Frontiers in Molecular Biosciences · 2021 · Review · CC BY

doi:10.3389/fmolb.2021.711227

Abstract

Copper is essential for life processes like energy metabolism, reactive oxygen species detoxification, iron uptake, and signaling in eukaryotic organisms. Mitochondria gather copper for the assembly of cuproenzymes such as the respiratory complex IV, cytochrome c oxidase, and the antioxidant enzyme superoxide dismutase 1. In this regard, copper plays a role in mitochondrial function and signaling involving bioenergetics, dynamics, and mitophagy, which affect cell fate by means of metabolic reprogramming. In mammals, copper homeostasis is tightly regulated by the liver. However, cellular copper levels are tissue specific. Copper imbalances, either overload or deficiency, have been associated with many diseases, including anemia, neutropenia, and thrombocytopenia, as well as tumor development and cancer aggressivity. Consistently, new pharmacological developments have been addressed to reduce or exacerbate copper levels as potential cancer therapies. This review goes over the copper source, distribution, cellular uptake, and its role in mitochondrial function, metabolic reprograming, and cancer biology, linking copper metabolism with the field of regenerative medicine and cancer.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Mitochondria behave as biological microchips and constitute an integrated metabolic circuit that receives, processes, and transmits various signals to manage cell fate, that is, cellular proliferation, differentiation, and death. Beyond ATP and heat generation, mitochondria are directly involved in the epigenetics and transcriptional control of gene expression to rewire cell metabolism to new environmental conditions.

The power of mitochondria and their ability to control cell metabolism and fate are based on the generation of the proton motive force (PMF) by the electron transport chain (ETC), which localizes in the inner mitochondrial membrane (IMM). The ETC is composed of the respiratory complex I (CI) NADH dehydrogenase, complex II (CII) succinate dehydrogenase, complex III (CIII) ubiquinol cytochrome c reductase, complex IV (CIV) cytochrome c oxidase, and the mobile electron carriers: coenzyme Q and cytochrome c. The ETC can be found in different configurations or arrays, varying from individual complexes to supramolecular associations, called supercomplexes or respirasomes, that are typically built of a monomer of CI, a dimer of CIII, and up to four monomers of CIV (I1III2IV0-4). Unknown factors regulate the ratio between individual and assembled complexes, but it is likely to be dependent on cell physiology and energetic needs.

The proper assembly and functioning of the ETC is copper dependent. This transition metal is a prosthetic group of CIV and plays a direct role in the generation of the PMF. Furthermore, copper is a cofactor of the copper/zinc superoxide dismutase (SOD1), a protein located in both the cytosol and the mitochondrial inner membrane space to relieve the ETC-generated ROS (for the mitochondrial matrix ROS, there is an Mn-superoxide dismutase, SOD2). The indirect role of copper on mitochondrial function is related to the mitochondrial iron uptake since it is a cofactor of ferroxidases. Iron transport is the key for iron–sulfur (FeS) cluster assembly and heme biosynthesis.

Hallmarks of dysfunctional copper metabolism are Wilson’s and Menkes diseases which are inherited disorders. Patients with Wilson’s disease accumulate copper in the liver due to the defective protein transporter, ATP7B. Copper overload produces liver cirrhosis, neurodegeneration, and anemia mostly via the exacerbation of hydroxyl radical production by the Fenton and Haber–Weiss reactions. Copper toxicity decreases mitochondrial respiration and induces apoptosis. On the other hand, Menkes disease features mutations in the transporter ATP7A which affect the release of copper from the enterocyte to the bloodstream, causing a severe copper deficiency that in most of cases results in death due to CIV and SOD1 dysfunction. Common clinical manifestations of copper deficiency are anemia, bone marrow dysplasia, neutropenia, and neuromyelopathy, and the appearance of enlarged mitochondria. These giant mitochondria or mega-mitochondria have been described in early precursors of the bone marrow, hepatocytes, and myocardium under copper deprivation, copper chelator treatments, and starvation in humans and rats. A mild copper deficiency in a murine model evoked mitochondrial adaptive responses involving the oxidative phosphorylation system (OXPHOS) remodeling and mitochondrial dynamic alterations, with upregulation of fusion proteins MFN-2 and OPA1 associated with a particular big mitochondrial morphology including normal and swollen mitochondria. Also, the generation of bigger mitochondria after copper deficiency in erythropoietic cells, cell line K562 and primary human CD34+, was related to the induction of mitochondrial fusion through upregulation of MFN-2 and OPA1.

Although heavy copper deficiency and overload have been associated with exacerbated ROS production and cell death due to mitochondrial dysfunction, noncytotoxic variations of the cellular copper levels may influence cell proliferation or differentiation through the reprogramming of mitochondrial metabolism, which can manage the balance between glycolysis and oxidative phosphorylation as well as the production of ROS, making the cellular environment oxidative. This exciting topic links copper metabolism with the field of regenerative medicine and cancer. In this review, we analyzed the acquisition of copper by the organisms and cells and the role of copper on mitochondrial function involving bioenergetics, dynamics, and mitophagy, and how this affects cell fate through metabolic reprogramming.

Copper Uptake and Physiology

Copper is mainly obtained from solid foods (Supplementary Table S1, Supplementary Material) and drinking water. The recommended intake of copper in humans should be less than 1.5 mg/d since 0.8 mg/d is enough to regulate and maintain copper status in the body. After the digestion of foods in the stomach and duodenum, copper is absorbed by cells of the intestinal mucosa, the enterocytes, which are also responsible for releasing copper into the blood plasma. When in excess, the ingested copper will be directly excreted through the feces, but when in lack, cellular mechanisms will be activated to allow greater intestinal uptake. The uptake efficiency of this metal is high, reaching 55–75% in adults. Of note, copper concentration is tissue-dependent, varying between 3 mg (kidneys) and 46 mg (skeleton) (average adult ≈70 kg). Thus, the use of copper is different for each cell, and the effects produced by the imbalances of this metal will be tissue-specific. SupplementaryTable S1 (Supplementary Material) shows the amount of copper found in different kinds of food.

There are two phases for copper distribution into the organism. Phase one: from food to the liver and kidneys via albumin and transcuprein. Phase two: from liver to other tissues and organs, such as heart, lungs, brain, and others via ceruloplasmin. The excess of copper must return to the liver, where it is again processed and incorporated into the bile which is the primary pathway for copper elimination from the body. However, some other fluids may transport copper to the intestine for excretion, such as the gastric and duodenal fluid. SupplementaryTable S2 (Supplementary Material) shows the concentrations of copper present in human fluids. Bile has the highest level of copper after blood. Copper entering the digestive tract through bile and other fluids becomes almost five times greater than copper consumed in the diet. However, only about 0.5–1.0 mg Cu is excreted. Most of it, about 4.5–5.5 mg Cu, is reabsorbed to maintain homeostasis of this metal.

Copper is transported inside the cell by the CTR1 (copper transport protein) transporter and then delivered to ATOX1 (antioxidant 1 copper chaperone) and CuL (low molecular weight copper ligand). The latter transports copper into mitochondria, specifically to COX17 (copper chaperone of cytochrome C oxidase [COX]) and CCS1 (copper chaperone of SOD1). Figure 1 shows the mechanisms of intracellular copper transport in human cells.

Getting Copper Into Mitochondria

Mitochondria need copper mainly for complex IV (COX) and SOD1 among other proteins (Table 1). CIV has two copper ions and is involved in the generation of the PMF and the complete reduction of oxygen to water in the ETC; SOD1 has one copper ion and is an antioxidant enzyme dealing with anion superoxide. In eukaryotes, mitochondrial copper is stored in the cytosolic anionic ligand (CuL) complex, and its release requires high regulation for the efficient metalation of COX and SOD1. This highly regulated mechanism is probably due to the limited availability of this ion in the cytosol and the need for an immediate source of copper for the assembly of COX.

Copper delivery into mitochondria is performed by the CuL, which is a non-proteinaceous low molecular weight complex found in the cytosol and the mitochondrial matrix. The biochemical properties of the CuL are conserved from yeasts to humans, debating that its functional significance started early in evolution. It is currently thought that the binding of copper (copper-free) to the CuL in the cytosol triggers its translocation to the mitochondrial intermembrane space (IMS) by means of the solute carrier family 25 member 3 (SLC25A3), the mammalian homolog of yeast Pic2. CuL in the matrix is finally translocated across the IMM to IMS by an unknown transporter to metalate SOD1 and COX.

In the mitochondrial matrix, copper is present in much higher quantities than required for metalation of COX and SOD1, suggesting that the matrix copper pool would represent a storage reserve for delivery to the IMS. The ability of the CuL to increase or decrease its size due to changes in cellular copper levels indicates that the CuL may be a dynamic regulator that responds to changes in cellular copper concentrations. This function allows mitochondria to assure the presence of a constant supply and reserve of copper for metalation of their biological targets, under different physiological processes. The proper functioning of this signaling pathway also depends on proteins or secondary messengers that monitor and report the functional status of mitochondrial inner membrane proteins capable of sensing stimuli and transducing signals, such as copper-binding integral inner membrane proteins: COX11, SCO1, and SCO2. Also, the COX assembly factors which are located in the IMS are soluble cysteine-rich proteins: COX17, COX19, COX23, and PET191. As a potential mechanism to stimulate OXPHOS metabolism, copper may directly act on the ETC to modulate the assembly or disassembly of respiratory complex IV. Indeed, complex IV serves as a metal sensor in the regulation of respiratory rates. Supporting this mechanism, copper deficiency reduces the expression and activity of complex IV, but not the other respiratory complexes. Regarding copper overload, the current results showed an increase in complex IV protein expression. Complex IV is made up of 11 protein subunits and requires 18 assembly factor proteins for accurate assembly. A recent report showed that copper is able to rescue complex IV assembly in the mutant mouse deficient in the cytochrome assembly factor, COA6. Therefore, copper helps to assemble complex IV to respond to energy demands. More complex IV assembly will enhance other complex assemblies, as has been reported for complex I.

Copper deficiency, on the other hand, interferes with COX biosynthesis, producing a decrease in mitochondrial ATP production, which causes remodeling of ETC complexes, represses respiration, and creates a reduction in the efficiency of oxygen utilization. It has been observed that as COX biosynthesis increases, other complexes tend to increase, such as complex I. In our laboratory, we observed that there is a considerable increase of all ETC complexes by adding a noncytotoxic copper concentration to K562 cells.

Copper Has a Key Role in Cu/Zn SOD1 and COX Assembly

SOD enzymes have the primary responsibility for the dismutation of superoxide anions to hydrogen peroxide in cells. They have copper and zinc as a metal cofactor (SOD1 and SOD3), although there also exist variations with manganese in eukaryotes (SOD2) and with iron and nickel in bacteria and protists. In humans, there are three isoforms, that is, SOD1, SOD2, and SOD3. SOD1 is mostly located in the cytosol, but 5–10% can be found in the mitochondria. SOD2 localizes in the mitochondrial matrix and SOD3 in the extracellular fluid. Although SOD2 is the predominant superoxide dismutase in the mitochondrial matrix, SOD1 is critical to the control of oxidative stress in the mitochondrial intermembrane space. The relevance of the antioxidant proteins and SODs is given by the control of ROS, which are known to regulate cell signaling.

SOD1 is a homodimer having a binuclear copper and zinc site in each subunit, which forms a narrow channel where the dissociation of 2O2 − to H2O2 is carried out. SOD1 is mostly metalated in the cytosol and remains in the cytosol. However, mitochondria-targeted SOD1 must first enter as an apoprotein (without copper) to be metalated in the IMS by CCS1. CCS1 is a small polypeptide with three domains; domains 1 and 3 bind copper, while domain 2 is the key to the interaction with SOD1. The transient interaction is mediated by domains 2 and 3 of CCS1. Figure 2 shows the place where CuL delivers copper to CCS1 inside the mitochondria.

COX is the terminal enzyme of the ETC and catalyzes the reduction of oxygen to water. It consists of 13 subunits. COX1 (MT_CO1), COX2 (MT-CO2), and COX3 are encoded in the mitochondrial DNA and form the COX catalytic center. The nuclear genome encodes the remaining ten subunits. The catalytic center of the enzyme contains 3 copper ions located in 2 copper centers, 2 copper ions in the CuA center, and 1 in the CuB center. Furthermore, two heme groups (α and α3) are also needed. The catalytic core is responsible for the oxidation of cytochrome c and the reduction of oxygen to water.

COX17 initiates the copper transfer reactions for COX metalation in the IMS, which acquires copper from the CuL and requires additional COX11, SCO1, SCO2, and COA6. COX11 metalates the CuB site in COX1, and SCO1, SCO2, and COA6 metalate the CuA site in COX2. Once copper redox cofactors and heme groups are added into COX1 and COX2, the remaining subunits are added for final maturation (Figure 2). COA6 enables COX biogenesis as a thiol-reductase for copper to reduce disulfide bridges of critical cysteine residues in SCO1 and SCO2 metallochaperones in mitochondria. In this review, we analyzed the protein–protein interactions (PPIs) of the copper network in mitochondria with the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING). The PPI network consisted of 20 nodes and 57 edges. The neighborhood connectivity of the nodes has an average of 7 neighbors (Figure 3). The interaction network shows that assembly and copper metalation of COX and SOD1 in mitochondria are very intricate. When COX1 is inserted in the mitochondrial membrane, SURF1 adds the heme group into COX1, and COX11 facilitates the formation of the CuB site. Copper for CuB is donated to COX11 by COX17 at the COX11 binding site right after cysteine sulfides are reduced by COX19. On the other hand, COX2 facilitates the maturation of the CuA site when it is bound to a protein complex composed of COX20, COA6, SCO1, and SCO2. Copper is required to be transferred from COX17 to SCO1 where the oxidoreductase activity of SCO2 on COX2 cysteine is considered fundamental. Likewise, these reactions are associated with COA6 which reduces COX2 and SCO1, allowing copper binding. The network suggests that the interaction of COA6 with COX17, SURF1, SCO1, SCO2, and MIA4 (CHCHD4) appears to be the entry point for cysteine-containing chaperones such as COA6, COX17, and COX19.

Role of Copper on Mitochondria and Cell Fate Determination

Hematopoietic stem cells (HSCs) and their fate are highly dependent on the mitochondrial metabolism. Mitochondria are responsible for metabolic reprograming needed for the commitment and differentiation of HSCs into different cell lineages, beyond energy production. In erythropoiesis, mitochondria are also involved in heme and hemoglobin biosyntheses. Typical mammalian HSCs remain quiescent in the hypoxic zone of the bone marrow (endosteal niche) to favor self-renewal, a process governed by the stabilization of the hypoxia-inducible factor-1 alpha (HIF-1α) protein and consequent heterodimerization with HIF-1ß to activate transcription in many target genes, including glycolytic enzymes. Thus, HSCs and embryonic stem cells have a minimal basal metabolism relying mainly on glycolysis, while mitochondrial respiration is low to avoid the generation of reactive oxygen species (ROS). Transition from glycolysis to OXPHOS and then from self-renewal to differentiation is dependent on the presence of oxygen, mitochondrial respiratory substrates, and the generation of mitochondrial ROS. Furthermore, the participation of mitochondrial fusion and fission events, the so-called mitochondrial dynamics (MtDy), and the mitochondrial permeability transition pore (mPTP) have been involved in this metabolic reprogramming.

Since respiratory complex IV has two copper sites that are essential for its function, its activity can be easily manipulated by either copper removal/chelation or copper overload, affecting the overall purpose and assembly of the ETC. Thus, managing the cellular copper level seems a simple way for metabolic reprograming switching from glycolysis to OXPHOS, and vice versa, to control cell fate. In this regard, copper imbalances cause anemia, neutropenia, thrombocytopenia (decreased blood platelets), myelodysplastic syndrome, and leukemia due to alterations in the differentiation process of the hematopoietic progenitor cells. In hematopoietic stem cells (HSCs), low copper delayed differentiation and stimulated cell expansion. Since the lack of copper promotes cell expansion, it has been proposed to be useful for ex vivo stem cell expansion which is yearned for cell therapy. At the mitochondrial level, the use of copper chelators results in decreased COX levels and mitochondrial and cellular ROS levels, the activation of glycolysis, and the appearance of giant mitochondria in erythropoietic cell lines and primary EPO-induced CD34 + cell differentiation. This metabolic change could allow their survival and cellular proliferation while awaiting the ideal conditions to continue their differentiation. Copper deficiency alters metabolic reprogramming in differentiating HSCs, reversing to an immature phenotype related with erythroid progenitor cell expansion, with low oxygen consumption, low ROS generation, and high membrane potential. In addition, copper deficiency has been associated with increased expression of the mitochondrial fusion proteins such as MFN1, MFN2, and OPA1 (optic atrophy 1), and increased mitochondrial membrane potential in K562 and EPO-induced CD34 + cells. In our laboratory, we generated a model of copper deficiency in C57 black mice with a BCS treatment that showed mild signs of anemia and reduced the expression of ceruloplasmin, ATP7B, and CIV, as previously reported by other groups. Also, the BCS-treated mice had more oxidized proteins, upregulation of the MFN2 protein, OXPHOS remodeling from supercomplexes to individual complexes, and higher oxygen consumption rates. Besides, the liver showed large mitochondria with a mix of average, balloon, and butternut squash mitochondria. The butternut squash mitochondria showed features between normal and swollen mitochondria, which are likely an intermediate state between the two phenotypes. It has also been reported that copper depletion with TEPA (tetraethylenepentamine) favored the maintenance and expansion of HSCs for erythroid differentiation.

On the other hand, individuals with high levels of copper in their blood showed altered hematological parameters with an increased number of proerythroblasts (early stage of erythropoietic differentiation) and a decreased number of orthochromatophilic erythroblasts (advanced phase of erythropoietic differentiation). High copper content has been associated with hemolysis because of its direct effect on the ETC and increased generation of oxidative stress. This could trigger a compensatory mechanism by accelerating the erythropoietic process and releasing immature cells into the bloodstream. High copper levels are then associated with mitochondrial dysfunction and cell death. However, noncytotoxic copper overload has been described to improve mitochondrial function by stimulating the biogenesis and assembly of complex IV along with the generation of a physiological amount of ROS in the erythropoietic cell line K562. This process stimulated mitochondrial turnover by mitophagy and mitochondrial biogenesis, resulting in highly active mitochondria overpacked with OXPHOS proteins for ATP synthesis. Thus, physiological ROS generation has been considered an adaptive response to produce adjustments in signaling pathways related to proliferation, metabolic adaptation, cell motility, adaptations to hypoxia, and angiogenesis.

Cellular copper levels, either in excess or lack, altered mitochondrial function in stem cells and many other cell types having an impact on either proliferation or differentiation. Figure 4 represents the metabolic reprogramming of HSCs toward expansion or differentiation according to intracellular copper levels. A lack of copper will induce cell expansion, a noncytotoxic copper overload, and differentiation. Furthermore, Tables 2, 3 show several primary cells and cell lines that have been exposed to different copper concentration or chelators and assayed for cell proliferation or differentiation.

Copper Role in Cancer

Metabolic reprogramming can go from differentiated to proliferative cells as it happens in cancer cells and induced pluripotent stem cells (iPSCs), where the cell metabolism switches from OXPHOS to aerobic glycolysis (Warburg effect). Regarding mitochondria in cancer cells, they displayed a stem cell-like phenotype, that is, low oxygen consumption and low ROS, although they displayed higher membrane potential than healthy cells.

The remarkable change in the metabolism that occurs in cancer cells has been associated, among other factors, with the management of copper and proteins that use it. An example of this is obtained by observing the high levels of ceruloplasmin found in various forms of cancer, such as lymphomas, breast cancer, and gastrointestinal cancer, and ceruloplasmin levels have been found to be increased 4 to 8 times during malignant progression, returning to normal levels after tumor regression. Copper levels increase three times in blood plasma, relating to tumor burden, progression, incidence, invasion, and reoccurrence of the disease. The human Cu proteome, with 54 Cu-binding proteins, are up- or downregulated in 18 cancer types (thymus, head and neck, esophagus, adrenal gland, bladder, stomach, soft tissue, kidney, pancreas, bile duct, liver, prostate, cervix, breast, uterus, thyroid, colorectal, and lung), showing intricate patterns.

Angiogenesis is the development of new blood vessels which are required for tumor growth. Cancer cells have developed ways to synthesize and release their own angiogenic stimulants or to recruit endothelial cells for the same purpose.

Copper is a potent stimulator of the angiogenic process by the activation of angiogenic factors like the interleukin (IL)-1, IL-6, and IL-8; tumor necrosis factor alpha (TNF-α); angiogenin; the basic fibroblast growth factor (bFGF); fibronectin; and the vascular endothelial growth factor (VEGF), which are critical for tumor angiogenic developments. Copper sulfate (CuSO4) combined with increasing doses of VEGF or FGF-2 revealed synergistic effect in endothelial cells grown in a 3D culture system with enhanced collagen fiber deposition providing complexity of angiogenic networks. Copper-coated disks inserted subcutaneously in rats stimulated a high and extended-release of interleukin-1α (IL-1α) and low quantities of IL-1β by recruited cells. HIF-1 transcriptional activity requires the accumulation of HIF-1α following inhibition of prolyl hydroxylases. This inhibition is generated by hypoxia, and chemical hypoxia can be generated by cobalt. Copper chelation with tetraethylenepentamine alters the transcriptional activity of HIF-1α, decreasing the mRNA and protein expression of VEGF, which is rescued by 25 μM CuSO4. Also, CCS1 gene silencing blocked VEGF expression, revealing copper requirement for cobalt-activated transcriptional activity of HIF-1α in promoting the expression of VEGF. Angiogenin-bound copper is a strong inducer of blood-vessel development, and it binds to endothelial cell receptors and extracellular matrix components. In vitro, copper sulfate incubation stimulates human umbilical vein endothelial cell proliferation and migration. In vitro, copper salts could induce the synthesis of the fibronectin matrix associated with angiogenesis. The study of the mechanism of angiogenesis in the adult organism, through a rabbit cornea model, implanted with 10–75°μg of copper sulfate pellets in the corneal stroma, induced long-lasting and dose-dependent neovascularization, showed that copper directly stimulates angiogenesis, and it is helpful in the evaluation of antiangiogenic agents. The expression of some angiogenic growth factors and cytokines is reduced when copper levels are decreased. Cerebral neoplasms sequester copper, utilizing a rabbit brain tumor model, and showed that normocupremic animals formed big vascularized VX2 carcinomas, while in copper depleted by diet- and penicillamine (CDPT)-treated rabbits, the tumors developed were small, circumscribed, and relatively avascular. Metabolic and pharmacologic removal of copper overcomes cerebral tumor angiogenesis.

With these antecedents, the concept of antiangiogenic therapies as cancer treatments has begun, although a phase two trial of copper depletion by diet and penicillamine as antiangiogenic therapy of glioblastoma multiforme did not improve survival in patients. Since it was discovered that tumor development is dependent on the formation of new blood vessels, the mechanisms that regulate angiogenesis continue to be investigated.

Many angiogenic promoters appear to be dependent on copper concentrations. They control various endogenous stimulators by acting as a cofactor, leading to the use of copper chelators as therapeutic strategies with antiangiogenic function. The most used copper chelators in tests are D-Pen (d-penicillamine) and TM (tetrathiomolybdate). D-Pen is an effective copper chelator and has antiangiogenic properties. In addition, it can inhibit essential growth factors (VEGF and FGF), requiring copper as a cofactor. However, in the phase two trial, two-month treatment with a copper-deficient diet combined with D-pen as antiangiogenic therapy for glioblastoma did not significantly increase the patients’ survival, despite effective hypocupremia.

On the other hand, trials in rodents showed that by decreasing copper levels using TM, there was a sharp decrease in angiogenesis. A phase two trial with TM in patients with advanced kidney cancer concluded that this treatment was well tolerated, decreased copper concentrations in all patients, and that 31% of patients showed stability in the disease for at least 6 months. TM reduces the secretion of IL-6 and bFGF by head and neck SCC (HNSCC) cell lines in vitro. Also, in a rat aortic ring assay, the HNSCC cell lines treated with TM decreased endothelial cell chemotaxis, tubule formation, and neovascularization. TM induced mild copper deficiency in the phase I clinical trial in patients with metastatic cancer treated with a dose of 120 mg/day, followed by ceruloplasmin decrease to 20% baseline without toxicity. Then, a phase II clinical trial in patients with malignant pleural mesothelioma received TM at 180 mg/day, starting 4–6 weeks post-surgery for 15 months. After 34 days, this dosage decreased ceruloplasmin levels from 45 mg/dl to 13 mg/dl. This mild copper deficiency decreases VEGF levels in the serum from an average of 2086 to 1,250 pg/ml, and patients showed encouraging results about overall survival. There must be several mechanisms by which the decrease of copper using TM inhibits tumor angiogenesis. For example, TM-treated SUM149 (inflammatory breast cancer cell line) cells released significantly lower amounts of 5 angiogenic factors (VEGF, FGF, IL1, IL6, and IL8) than untreated cells. TM has also shown to inhibit endothelial cell differentiation and to suppress NFκB protein levels and its transcription (NFκB is known to regulate many genes involved in tumor invasion, angiogenesis, and metastasis).

In the murine HCC (human hepatocellular carcinoma) xenograft model, tumor development and angiogenesis were suppressed by trientine, a copper-chelating agent. Trientine treatment in combination with a copper-deficient diet caused a noticeable inhibition of neovascularization and increased apoptosis in the HCC tumor.

The depletion of mitochondrial copper induces a metabolic reprogramming that shifts from oxidative to glycolytic metabolism and reduces energy production. The above is an effective therapy against cancer types that depends on OXPHOS. Copper-depleting nanoparticle (CDN) targeted on mitochondria causes a metabolic shift from respiration to glycolysis in triple-negative breast cancer (TNBC). CDNs are composed by a copper-depleting moiety (CDM) and a semiconducting polymer nanoparticle (SPN). The CDM is composed of N,N-Bis (2-pyridinylmethyl)-1,2-ethanediamine linked to tricarbocyanine. SPN consists of semiconducting polymers and phospholipid-polyethylene glycol (PEG). CDN administration inhibits tumor growth and improves survival of three mouse models of TNBC.

Abnormal copper accumulation in cancer cells can help to distinguish transformed cells from healthy ones and can be used as targets for novel chemotherapeutic agents, such as the use of organic copper compounds in antitumor treatments has been investigated as cytotoxic agents and showed antitumor activity, such as Cu(II) thiosemicarbazide complexes, Isatin–Schiff base Cu(II) complexes [(4,7-dimethyl-1,10-phenanthroline) (glicinate)], Cu(II) nitrate complex, Casiopeina II-gly, and imidazole, benzimidazole, and pyrazole Cu(II) complexes. The mode of action of these compounds is through producing high levels of ROS, mitochondrial toxicity, and DNA interactions, inhibiting cell proliferation and producing apoptosis. For example, Casiopeínas® are mixed chelate copper (II) compounds ([Cu(N-N) (O-O)]NO3 or [Cu(N-N) (O-N)]NO3) with antitumor potential. Casiopeínas® alter mitochondria bioenergetics, with reports of inhibition of respiration and ATP synthesis, mitochondrial swelling, loss of mitochondrial membrane potential, and cytochrome c release. Another example of this is found in the use of D-Pen together with cupric sulfate. This mixture was able to cause a dose-dependent cytotoxicity in human cancer cells..

Cancer cells are sensitive to proteasome inhibition, suggesting good potential as anticancer agents for copper complexes. Amino acid Schiff base–copper (II) complexes inhibit the chymotrypsin-like activity of the proteasome, producing a buildup of proteasome target proteins Bax and IκB-α, therefore inducing growth inhibition and apoptosis. Cyclic dithiocarbamate (DTC) ligands, such as the neutral Cu(II) derivatives of the type [Cu(DTC)2], show remarkable anticancer activity (IC50≤1 µM). Cu(II) ion increases the activity of 8-hydroxyquinoline derivatives in inhibiting the chymotrypsin-like activity of the proteasome and induces growth inhibition and apoptosis. The Cu(II) ion complex with glycoconjugate DTC shows potential applications in targeted chemotherapy; in particular, the CuGlu ([CuII(DTC-β-d-glucose)2]) revealed an exciting IC50 (2.0 ± 0.1 µM) value for the HCT116 human colorectal carcinoma cell line. Estrogen-functionalized Cu(II) complexes are potent anticancer agents with low IC50 values. Their cellular uptake occurred via passive diffusion, and their mechanisms involved high DNA intercalation, intense DNA cleaving activity, and stimulation ROS production. [Cu(l-proline methyl ester DTC)2] copper compounds into micelles with a cancer-targeting biomolecule are presented as a proper “Trojan Horse” strategy for the delivery of Cu-DTC chemotherapeutics.

Mechanisms of Copper Action on Tumor Development

It has been shown that exposure to high levels of copper in water (1.3 mg/L maximum levels allowed in public water supplies) can enhance tumor progression but not of forming new tumors and decreasing the intake of this metal stops the development of the disease, indicating that copper is not capable of producing transformation but is a necessary nutrient for these cells. That is why copper has been described as a stimulator of tumor development and not an initiator of transformation, as it promotes several processes related to cancer.

Several types of cancer cells possess very high levels of the transmembrane transporter CTR1, explaining how these cells obtain the high concentrations of copper. Cancer cells treated with copper chelator treatments have dramatically decreased ATP production even when there is an increase in glycolysis, indicating that these cells still rely on OXPHOS. Thus, these elevated levels of copper can regulate the production of ATP by OXPHOS to meet the demands of the accelerated proliferation found in solid cancers, indicating that copper may be a limiting nutrient for tumor development. The high copper content could be activating the function as a transcription factor of ATOX1, further enhancing cell proliferation.

ATOX1 is established to perform a vital function in copper homeostasis. Moreover, ATOX1 shows high expression in different cancers and has been described to present a critical function in angiogenesis. Remarkably, ATOX1 is a copper-dependent transcription factor (requires copper binding) that stimulates the expression of NADPH oxidase p47phox and Cyclin D1, relating to increased ROS generation and proliferation, respectively. The nuclear localization of ATOX1 is associated with the severity of metastatic colorectal cancer. Stimulation of colon cancer metastasis with activin A promotes ATOX1 nuclear translocation in metastatic SW620 and nonmetastatic SW480 colon cancer cell lines. Knockdown of ATOX1 in SW620 decreased ROS generation and colony formation through a decreased expression of NADPH oxidase p47phox and Cyclin D1. Individual cell migration is an early step in breast cancer metastasis; thus, ATOX1 silencing decreases the breast cancer cell migration velocity via coordinated copper transport in the ATP7A-LOX (proenzyme of lysyl oxidase) axis.

Considering possible copper effects on tumor development, the gene TP53—which encodes for the tumor suppressor protein p53—should be mentioned, as it is the most frequently mutated protein in human cancers. The protein p53 is a transcription factor that possesses a single zinc ion near its DNA-binding interface, and deficient zinc through competition with copper causes p53 to misfold, which results in functional loss of transcriptional activity.

Other mechanistic insight about copper action in cancer would be the oncogenic BRAFV600E that phosphorylates and activates the MEK1 and MEK2 kinases, which in turn phosphorylates and activates ERK1 and ERK2 kinases, stimulating the MAPK (mitogen-activated protein kinase) pathway to promote cancer. Alterations of the MEK1 interaction with copper and decrease of copper influx shooting down CTR1 decrease BRAFV600E driven signaling and tumorigenesis.

Moreover, the autophagy signaling is implicated in cellular proliferation, and copper is necessary for the activity of the ULK1 and ULK2 (ULK1/2) autophagic kinases, by directly binding Cu to ULK1/2. Elevated intracellular copper levels are related to starvation-induced autophagy and are enough to upregulate the ULK1 kinase activity and autophagic flux. Copper-treated K562 cells showed reduced levels of protein P62, indicating an increased autophagic flux and mitochondrial fusion, which is restored to basal levels by TBAP (antioxidant molecule that mimics SOD2) treatment, suggesting that copper-induced ROS speeds up mitochondrial turnover. The loss of the copper transporter CTR1 decreased the growth and survival of KRASG12D-driven lung tumors, which are reliant on Cu-ULK1 binding and are coupled to reduced autophagy and signaling. This work established the molecular basis of copper chelation to prevent autophagy signaling, copper-dependent ROS generation (Fenton reaction), and glycolytic metabolism from limiting proliferation and improving cancer patients' survival.

Interestingly, copper also has a role in regulating the programmed death ligand 1 (PD-L1), which is overexpressed by cancer cells to protect themselves from antitumor immune responses. Copper supplementation in cancer cells enhanced PD-L1 expression, driving cancer immune evasion, while copper chelation promoted ubiquitin-mediated degradation of PD-L1 and increased the number of tumor-infiltrating CD8+T and natural-killer cells.

The presence of significant high serum copper levels in nonalcoholic fatty liver disease (NAFLD) in cirrhotic patients increased cell growth, migration, and invasion of liver cancer cells through the modulation of the MYC/CTR1 axis (MYC proto-oncogene, bHLH transcription factor/copper transport protein). Figure 5 summarizes the main findings of copper action in cancer.

Final Thoughts

As largely discussed in this review, cellular copper concentration has a direct impact on cell proliferation, differentiation, or cell death. Copper property to control cell fate has been exploited by modern medicine in the field of stem cell–based regenerative medicine as well as in the fight against cancer. The main action of copper is at the level of mitochondrial function and metabolism because copper is a prosthetic group of respiratory complex IV. Copper bioavailability has been shown to regulate both expression and activity of complex IV and then the balance between glycolysis and OXPHOS. Copper deficiency will favor glycolysis and cell proliferation, and a noncytotoxic copper overload, OXPHOS, and cell differentiation. However, the final outcome will be tissue- or cell-specific. Changes in mitochondrial metabolism also impact the amount intermediate metabolites, such as acetyl-CoA, citrate, α-ketoglutarate, ROS, and NAD+/NADH among others, which have a direct effect on the transcriptional and epigenetic regulation of cells, by means of mitochondria–nucleus retrograde communication. Copper-induced transcriptional regulation also occurs via ATOX1, a copper-dependent transcription factor associated with angiogenesis and tumor development. On the other hand, an excessive copper overload will induce a massive amount of ROS, due to Fenton and Haber–Weiss reactions, causing cell death via apoptosis or necrosis. Thus, copper action involves either going from mitochondrial-induced metabolic reprogramming to genetic reprogramming to change cellular phenotype, or cell death.

Pharmacological modulation of intracellular copper concentrations is effective to control stem cell expansion and/or differentiation for regenerative medicine as well as to control tumor growth and cancer development. Cancer cells have been shown to accumulate more copper than healthy cells and to be sensitive to proteasome inhibition. Therefore, many copper-based pharmacological strategies have been developed to eliminate cancer cells. Those include copper chelators, copper-depleting nanoparticles, and copper-based compounds which have been shown to be successful both in vitro and in vivo. Nevertheless, more basic and clinical research is still needed regarding cell-specific targeting and delivery of those copper compounds.

The study of copper on mitochondrial function and metabolism has opened a powerful and novel route for drug discovery and nanobiotechnology, not only for treating catastrophic diseases like cancer but also for protecting and/or improving mitochondrial activity and capacity. Remarkably, proper mitochondrial function is associated with healthy aging and the delay of aging-associated diseases.

References 194

  1. 1.

    Acín-Pérez R. Fernández-Silva P. Peleato M. L. Pérez-Martos A. Enriquez J. A. (2008 ). Respiratory Active Mitochondrial Supercomplexes. Mol. Cel 32, 529–53910.

    Not in our library10.1016/j.molcel.2008.10.021

  2. 2.

    Anderson A. J. Jackson T. D. Stroud D. A. Stojanovski D. (2019 ). Mitochondria-hubs for Regulating Cellular Biochemistry: Emerging Concepts and Networks. Open Biol. 9, 190126.

    Not in our library10.1098/rsob.190126

  3. 3.

    Arnal N. de Alaniz M. J. T. Marra C. A. (2012 ). Cytotoxic Effects of Copper Overload on suman-Derived Lung and Liver Cells in Culture. Biochim. Biophys. Acta (Bba) - Gen. Subjects 1820, 931–93910.

    Not in our library10.1016/j.bbagen.2012.03.007

  4. 4.

    Aston N. S. Watt N. Morton I. E. Tanner M. S. Evans G. S. (2000 ). Copper Toxicity Affects Proliferation and Viability of Human Hepatoma Cells (HepG2 Line). Hum. Exp. Toxicol. 19, 367–37610.

    Not in our library10.1191/096032700678815963

  5. 5.

    Bae B. Percival S. S. (1993 ). Retinoic Acid-Induced HL-60 Cell Differentiation Is Augmented by Copper Supplementation. J. Nutr. 123, 997–1002.

    Not in our library10.1093/jn/123.6.997

  6. 6.

    Baker Z. N. Cobine P. A. Leary S. C. (2017 ). The Mitochondrion: a central Architect of Copper Homeostasis. Metallomics 9, 1501–151210.

    Not in our library10.1039/c7mt00221a

  7. 7.

    Barrett S. De Franco M. Kellett A. Dempsey E. Marzano C. (2020 ). Anticancer Activity, DNA Binding and Cell Mechanistic Studies of Estrogen-Functionalised Cu(II) Complexes. JBIC J. Biol. Inorg. Chem. 25, 49–60.

    Not in our library10.1007/s00775-019-01732-8

  8. 8.

    Bigarella C. L. Liang R. Ghaffari S. (2014 ). Stem Cells and the Impact of ROS Signaling, Cambridge, England. Development 141, 4206–4218.

    Not in our library10.1242/dev.107086

  9. 9.

    Björkblom B. Adilbayeva A. Maple-Grødem J. Piston D. Ökvist M. Xu X. M. (2013 ). Parkinson Disease Protein DJ-1 Binds Metals and Protects against Metal-Induced Cytotoxicity. J. Biol. Chem. 288, 22809–22820.

    Not in our library10.1074/jbc.m113.482091

  10. 10.

    Blockhuys S. Celauro E. Hildesjö C. Feizi A. Stål O. Fierro-González J. C. (2017 ). Defining the Human Copper Proteome and Analysis of its Expression Variation in Cancers. Metallomics 9, 112–123.

    Not in our library10.1039/c6mt00202a

  11. 11.

    Blockhuys S. Zhang X. Wittung-Stafshede P. (2020 ). Single-cell Tracking Demonstrates Copper Chaperone Atox1 to Be Required for Breast Cancer Cell Migration. Proc. Natl. Acad. Sci. 117, 2014.

    Not in our library10.1073/pnas.1910722117

  12. 12.

    Bode A. M. Miller L. A. Faber J. Saari J. T. (1992 ). Mitochondrial Respiration in Heart, Liver, and Kidney of Copper-Deficient Rats. J. Nutr. Biochem. 3, 668–672.

    Not in our library10.1016/0955-2863(92)90088-z

  13. 13.

    Boekema E. J. Braun H-P. (2007 ). Supramolecular Structure of the Mitochondrial Oxidative Phosphorylation System. J. Biol. Chem. 282, 1–4.

    Not in our library10.1074/jbc.r600031200

  14. 14.

    Bolamperti L. Leone M. A. Stecco A. Reggiani M. Pirisi M. Carriero A. (2009 ). Myeloneuropathy Due to Copper Deficiency: Clinical and MRI Findings after Copper Supplementation. Neurol. Sci. 30, 521–524.

    Not in our library10.1007/s10072-009-0126-7

  15. 15.

    Bonnet S. Archer S. L. Allalunis-Turner J. Haromy A. Beaulieu C. Thompson R. (2007 ). A Mitochondria-K+ Channel Axis Is Suppressed in Cancer and its Normalization Promotes Apoptosis and Inhibits Cancer Growth. Cancer Cell 11, 37–51.

    Not in our library10.1016/j.ccr.2006.10.020

  16. 16.

    Boulet A. Vest K. E. Maynard M. K. Gammon M. G. Russell A. C. Mathews A. T. (2018 ). The Mammalian Phosphate Carrier SLC25A3 Is a Mitochondrial Copper Transporter Required for Cytochrome C Oxidase Biogenesis. J. Biol. Chem. 293, 1887–1896.

    Not in our library10.1074/jbc.ra117.000265

  17. 17.

    Brady D. C. Crowe M. S. Turski M. L. Hobbs G. A. Yao X. Chaikuad A. (2014 ). Copper Is Required for Oncogenic BRAF Signalling and Tumorigenesis. Nature 509, 492–496.

    Not in our library10.1038/nature13180

  18. 18.

    Brem S. Grossman S. A. Carson K. A. New P. Phuphanich S. Alavi J. B. (2005 ). Phase 2 Trial of Copper Depletion and Penicillamine as Antiangiogenesis Therapy of Glioblastoma. Neuro-Oncology 7, 246–253.

    Not in our library10.1215/s1152851704000869

  19. 19.

    Brem S. (1999 ). Angiogenesis and Cancer Control: From Concept to Therapeutic Trial. Cancer Control 6, 1–18.

    Not in our library10.1177/107327489900600502

  20. 20.

    Brem S. S. Zagzag D. Tsanaclis A. M. Gately S. Elkouby M. P. Brien S. E. (1990 ). Inhibition of Angiogenesis and Tumor Growth in the Brain. Suppression of Endothelial Cell Turnover by Penicillamine and the Depletion of Copper, an Angiogenic Cofactor. Am. J. Pathol. 137, 1121–1142.

    Not in our library

  21. 21.

    Brewer G. J. (2001 ). Copper Control as an Antiangiogenic Anticancer Therapy: Lessons from Treating Wilson's Disease. Exp. Biol. Med. 226, 665–673.

    Not in our library10.1177/153537020222600712

  22. 22.

    Brewer G. J. (2003 ). Copper in Medicine. Curr. Opin. Chem. Biol. 7, 207–212.

    Not in our library10.1016/s1367-5931(03)00018-8

  23. 23.

    Brewer G. J. Dick R. D. Grover D. K. LeClaire V. Tseng M. Wicha M. (2000 ). Treatment of Metastatic Cancer with Tetrathiomolybdate, an Anticopper, Antiangiogenic Agent: Phase I Study. Clin. Cancer Res. 6, 1–10.

    Not in our library

  24. 24.

    Brewer G. J. Hedera P. Kluin K. J. Carlson M. Askari F. Dick R. B. (2003 ). Treatment of wilson Disease with Ammonium Tetrathiomolybdate: Iii. Initial Therapy in a Total of 55 Neurologically Affected Patients and Follow-Up with Zinc Therapy. Arch. Neurol. 60, 379–385.

    Not in our library10.1001/archneur.60.3.379

  25. 25.

    Brustolin L. Nardon C. Pettenuzzo N. Zuin Fantoni N. Quarta S. Chiara F. (2018 ). Synthesis, Chemical Characterization and Cancer Cell Growth-Inhibitory Activities of Cu(ii) and Ru(iii) Aliphatic and Aromatic Dithiocarbamato Complexes. Dalton Trans. 47, 15477–15486.

    Not in our library10.1039/c8dt02965b

  26. 26.

    Brustolin L. Pettenuzzo N. Nardon C. Quarta S. Montagner I. Pontisso P. (2020 ). Labelled Micelles for the Delivery of Cytotoxic Cu(II) and Ru(III) Compounds in the Treatment of Aggressive Orphan Cancers: Design and Biological In Vitro Data. J. Inorg. Biochem. 213, 111259.

    Not in our library10.1016/j.jinorgbio.2020.111259

  27. 27.

    Bustos R. I. Jensen E. L. Ruiz L. M. Rivera S. Ruiz S. Ruiz S. (2013 ). Copper Deficiency Alters Cell Bioenergetics and Induces Mitochondrial Fusion through Up-Regulation of MFN2 and OPA1 in Erythropoietic Cells. Biochem. Biophys. Res. Commun. 437, 426–432.

    Not in our library10.1016/j.bbrc.2013.06.095

  28. 28.

    Cai H. Peng F. (2013 ). Knockdown of Copper Chaperone Antioxidant-1 by RNA Interference Inhibits Copper-Stimulated Proliferation of Non-small Cell Lung Carcinoma Cells. Oncol. Rep. 30, 269–275.

    Not in our library10.3892/or.2013.2436

  29. 29.

    Cerone S. I. Sansinanea A. S. Streitenberger S. A. Garcia M. C. Auza N. J. (2000 ). Cytochrome C Oxidase, Cu,Zn-Superoxide Dismutase, and Ceruloplasmin Activities in Copper-Deficient Bovines. Biol. Trace Elem. Res. 73, 269–278.

    Not in our library10.1385/bter:73:3:269

  30. 30.

    Chang C-R. Blackstone C. (2010 ). Dynamic Regulation of Mitochondrial Fission through Modification of the Dynamin-Related Protein Drp1 in Mitochondrial Research In Translational Medicine. Editors Wei Y. H. Tzeng C. R. Lee H. M., 34–39.

    Not in our library10.1111/j.1749-6632.2010.05629.x

  31. 31.

    Chen G-F. Sudhahar V. Youn S-W. Das A. Cho J. Kamiya T. (2015 ). Copper Transport Protein Antioxidant-1 Promotes Inflammatory Neovascularization via Chaperone and Transcription Factor Function. Scientific Rep. 5, 14780.

    Not in our library10.1038/srep14780

  32. 32.

    Chen X. Jennings D. B. Medeiros D. M. (2002 ). Impaired Cardiac Mitochondrial Membrane Potential and Respiration in Copper-Deficient Rats. J. Bioenerg. Biomembr 34, 397–406.

    Not in our library10.1023/a:1021258204921

  33. 33.

    Chen X. Medeiros D. M. Jennings D. (2005 ). Mitochondrial Membrane Potential Is Reduced in Copper-Deficient C2C12 Cells in the Absence of Apoptosis. Biol. Trace Elem. Res. 106, 51–63.

    Not in our library10.1385/bter:106:1:051

  34. 34.

    Chung J. Chen C. Paw B. H. (2012 ). Heme Metabolism and Erythropoiesis. Curr. Opin. Hematol. 19, 156–162.

    Not in our library10.1097/moh.0b013e328351c48b

  35. 35.

    Cobine P. A. Moore S. A. Leary S. C. (2021 ). Getting Out what You Put in: Copper in Mitochondria and its Impacts on Human Disease. Biochim. Biophys. Acta (Bba) - Mol. Cel Res. 1868, 118867.

    Not in our library10.1016/j.bbamcr.2020.118867

  36. 36.

    Cobine P. A. Ojeda L. D. Rigby K. M. Winge D. R. (2004 ). Yeast Contain a Non-proteinaceous Pool of Copper in the Mitochondrial Matrix. J. Biol. Chem. 279, 14447–14455.

    Not in our library10.1074/jbc.m312693200

  37. 37.

    Cobine P. A. Pierrel F. Bestwick M. L. Winge D. R. (2006a ). Mitochondrial Matrix Copper Complex Used in Metallation of Cytochrome Oxidase and Superoxide Dismutase. J. Biol. Chem. 281, 36552–36559.

    Not in our library10.1074/jbc.m606839200

  38. 38.

    Cobine P. A. Pierrel F. Winge D. R. (2006b ). Copper Trafficking to the Mitochondrion and Assembly of Copper Metalloenzymes. Biochim. Biophys. Acta (Bba) - Mol. Cel Res. 1763, 759–772.

    Not in our library10.1016/j.bbamcr.2006.03.002

  39. 39.

    Council N. R. Sciences C. L. Toxicology B. E. S. Water C. C. D. (2000 ). Copper in Drinking Water. Washington, DC: National Academies Press.

    Not in our library

  40. 40.
    Rapid copper acquisition by developing murine mesothelioma: decreasing bioavailable copper slows tumor growth, normalizes vessels and promotes T cell infiltration. · 2013
    Not checked
  41. 41.

    Cui L. Gouw A. M. LaGory E. L. Guo S. Attarwala N. Tang Y. (2021 ). Mitochondrial Copper Depletion Suppresses Triple-Negative Breast Cancer in Mice. Nat. Biotechnol. 39 (3), 357–367.

    Not in our library10.1038/s41587-020-0707-9

  42. 42.

    Dahlberg A. Delaney C. Bernstein I. D. (2011 ). Ex Vivo expansion of Human Hematopoietic Stem and Progenitor Cells. Blood 117, 6083–6090.

    Not in our library10.1182/blood-2011-01-283606

  43. 43.

    Dallman P. R. Goodman J. R. (1970 ). Enlargement of Mitochondrial Compartment in Iron and Copper Deficiency. Blood 35, 496–505.

    Not in our library10.1182/blood.v35.4.496.496

  44. 44.

    Daniel K. G. Gupta P. Harbach R. H. Guida W. C. Dou Q. P. (2004 ). Organic Copper Complexes as a New Class of Proteasome Inhibitors and Apoptosis Inducers in Human Cancer Cells. Biochem. Pharmacol. 67, 1139–1151.

    Not in our library10.1016/j.bcp.2003.10.031

  45. 45.
    Is There a Link between Mitochondrial Reserve Respiratory Capacity and Aging? · 2012
    No notice
  46. 46.

    Diaz F. Fukui H. Garcia S. Moraes C. T. (2006 ). Cytochrome C Oxidase Is Required for the Assembly/Stability of Respiratory Complex I in Mouse Fibroblasts. Mol. Cell Biol. 26, 4872–4881.

    Not in our library10.1128/mcb.01767-05

  47. 47.

    Dudkina N. V. Sunderhaus S. Boekema E. J. Braun H. P. (2008 ). The Higher Level of Organization of the Oxidative Phosphorylation System: Mitochondrial Supercomplexes. J. Bioenerg. biomembranes 40, 419–424.

    Not in our library10.1007/s10863-008-9167-5

  48. 48.

    Fibach E. Rachmilewitz E. (2008 ). The Role of Oxidative Stress in Hemolytic Anemia. Curr. Mol. Med. 8, 609–619.

    Not in our library10.2174/156652408786241384

  49. 49.

    Fischer A. C. Goode C. A. (1994 ). Interaction of Bovine Ceruloplasmin with Erythrocytes. Prep. Biochem. 24, 151–165.

    Not in our library10.1080/10826069408010089

  50. 50.

    Folkman J. Klagsbrun M. (1987 ). Angiogenic Factors. Science 235, 442–447.

    Not in our library10.1126/science.2432664

  51. 51.

    Folmes C. D. L. Dzeja P. P. Nelson T. J. Terzic A. (2012 ). Mitochondria in Control of Cell Fate. Circ. Res. 110, 526–529.

    Not in our library10.1161/res.0b013e31824ae5c1

  52. 52.

    Fong T. Vij R. Vijayan A. DiPersio J. Blinder M. (2007 ). Copper Deficiency: an Important Consideration in the Differential Diagnosis of Myelodysplastic Syndrome. Haematologica 92, 1429–1430.

    Not in our library10.3324/haematol.11314

  53. 53.

    Fontenay M. Cathelin S. Amiot M. Gyan E. Solary E. (2006 ). Mitochondria in Hematopoiesis and Hematological Diseases. Oncogene 25, 4757–4767.

    Not in our library10.1038/sj.onc.1209606

  54. 54.

    Formigari A. Gregianin E. Irato P. (2013 ). The Effect of Zinc and the Role of P53 in Copper-Induced Cellular Stress Responses. J. Appl. Toxicol. 33, 527–536.

    Not in our library10.1002/jat.2854

  55. 55.

    Fukai T. Ushio-Fukai M. (2011 ). Superoxide Dismutases: Role in Redox Signaling, Vascular Function, and Diseases. Antioxid. Redox Signaling 15, 1583–1606.

    Not in our library10.1089/ars.2011.3999

  56. 56.

    Gabreyes A. A. Abbasi H. N. Forbes K. P. McQuaker G. Duncan A. Morrison I. (2013 ). Hypocupremia Associated Cytopenia and Myelopathy: a National Retrospective Review. Eur. J. Haematol. 90, 1–9.

    Not in our library10.1111/ejh.12020

  57. 57.

    Gallagher C. H. Reeve V. E. Wright R. (1973 ). Copper Deficiency in the Rat. Effect on the Ultrastructure of Hepatocytes. Aust. J. Exp. Biol. Med. Sci. 51, 181–189.

    Not in our library10.1038/icb.1973.15

  58. 58.

    Gérard C. Bordeleau L-J. Barralet J. Doillon C. J. (2010 ). The Stimulation of Angiogenesis and Collagen Deposition by Copper. Biomaterials 31, 824–831.

    Not in our library10.1016/j.biomaterials.2009.10.009

  59. 59.

    Getz J. Lin D. Medeiros D. M. (2011 ). The Cardiac Copper Chaperone Proteins Sco1 and CCS Are Up-Regulated, but Cox 1 and Cox4 Are Down-Regulated, by Copper Deficiency. Biol. Trace Elem. Res. 143, 368–377.

    Not in our library10.1007/s12011-010-8858-z

  60. 60.

    Ghosh A. Trivedi P. P. Timbalia S. A. Griffin A. T. Rahn J. J. Chan S. S. (2014 ). Copper Supplementation Restores Cytochrome C Oxidase Assembly Defect in a Mitochondrial Disease Model of COA6 Deficiency. Hum. Mol. Genet. 23, 3596–3606.

    Not in our library10.1093/hmg/ddu069

  61. 61.

    Gletsu-Miller N. Broderius M. Frediani J. K. Zhao V. M. Griffith D. P. Sweeney J. F. (2011 ). Incidence and Prevalence of Copper Deficiency Following Roux-En-Y Gastric Bypass Surgery. Int. J. Obes. 36, 328.

    Not in our library10.1038/ijo.2011.159

  62. 62.

    Gonzalez-Ibanez A. M. Ruiz L. M. Jensen E. Echeverria C. A. Romero V. Stiles L. (2020 ). Erythroid Differentiation and Heme Biosynthesis Are Dependent on a Shift in the Balance of Mitochondrial Fusion and Fission Dynamics. Front Cel Dev Biol 8, 592035–35.

    Not in our library10.3389/fcell.2020.592035

  63. 63.

    Goodman J. R. Warshaw J. B. Dallman P. R. (1970 ). Cardiac Hypertrophy in Rats with Iron and Copper Deficiency: Quantitative Contribution of Mitochondrial Enlargement. Pediatr. Res. 4, 244–256.

    Not in our library10.1203/00006450-197005000-00003

  64. 64.

    Goodman V. L. Brewer G. J. Merajver S. D. (2004 ). Copper Deficiency as an Anti-cancer Strategy. Endocrine-Related Cancer 11, 255–263.

    Not in our library10.1677/erc.0.0110255

  65. 65.

    Goyens P. Brasseur D. Cadranel S. (1985 ). Copper Deficiency in Infants with Active Celiac Disease. J. Pediatr. Gastroenterol. Nutr. 4, 677–680.

    Not in our library10.1097/00005176-198508000-00033

  66. 66.

    Gregg X. T. Reddy V. Prchal J. T. (2002 ). Copper Deficiency Masquerading as Myelodysplastic Syndrome. Blood 100, 1493–1495.

    Not in our library10.1182/blood-2002-01-0256

  67. 67.

    Gregory C. Eaves A. (1978 ). Three Stages of Erythropoietic Progenitor Cell Differentiation Distinguished by a Number of Physical and Biologic Properties. Blood 51, 527–537.

    Not in our library10.1182/blood.v51.3.527.bloodjournal513527

  68. 68.

    Griffith D. P. Liff D. Ziegler T. R. Esper G. J. Winton E. F. (2009 ). Acquired Copper Deficiency: A Potentially Serious and Preventable Complication Following Gastric Bypass Surgery. Obes. (Silver Spring Md) 17, 827–831.

    Not in our library10.1038/oby.2008.614

  69. 69.

    Gudekar N. Shanbhag V. Wang Y. Ralle M. Weisman G. A. Petris M. J. (2020 ). Metallothioneins Regulate ATP7A Trafficking and Control Cell Viability during Copper Deficiency and Excess. Scientific Rep. 10, 7856.

    Not in our library10.1038/s41598-020-64521-3

  70. 70.

    Gullino P. M. (1986 ). Considerations on the Mechanism of the Angiogenic Response. Anticancer Res. 6, 153–158.

    Not in our library

  71. 71.

    Gupta A. Bhattacharjee A. Dmitriev O. Y. Nokhrin S. Braiterman L. Hubbard A. L. (2011 ). Cellular Copper Levels Determine the Phenotype of the Arg875 Variant of ATP7B/Wilson Disease Protein. Proc. Natl. Acad. Sci. U S A. 108, 5390–5395.

    Not in our library10.1073/pnas.1014959108

  72. 72.

    Gupte A. Mumper R. J. (2009 ). Elevated Copper and Oxidative Stress in Cancer Cells as a Target for Cancer Treatment. Cancer Treat. Rev. 35, 32–46.

    Not in our library10.1016/j.ctrv.2008.07.004

  73. 73.

    Halfdanarson T. R. Kumar N. Li C-Y. Phyliky R. L. Hogan W. J. (2008 ). Hematological Manifestations of Copper Deficiency: a Retrospective Review. Eur. J. Haematol. 80, 523–531.

    Not in our library10.1111/j.1600-0609.2008.01050.x

  74. 74.

    Hamza I. Faisst A. Prohaska J. Chen J. Gruss P. Gitlin J. D. (2001 ). The Metallochaperone Atox1 Plays a Critical Role in Perinatal Copper Homeostasis. Proc. Natl. Acad. Sci. United States America 98, 6848–6852.

    Not in our library10.1073/pnas.111058498

  75. 75.

    Hanahan D. Weinberg Robert A. (2011 ). Hallmarks of Cancer: The Next Generation. Cell 144, 646–674.

    Not in our library10.1016/j.cell.2011.02.013

  76. 76.
    The Role of Copper Chaperone Atox1 in Coupling Redox Homeostasis to Intracellular Copper Distribution · 2016
    No notice
  77. 77.

    Hirase N. Abe Y. Sadamura S. Yufu Y. Muta K. Umemura T. (1992 ). Anemia and Neutropenia in a Case of Copper Deficiency: Role of Copper in Normal Hematopoiesis. Acta Haematologica 87, 195–197.

    Not in our library10.1159/000204758

  78. 78.
    The Mitochondrial Metallochaperone SCO1 Is Required to Sustain Expression of the High-Affinity Copper Transporter CTR1 and Preserve Copper Homeostasis · 2015
    Not checked
  79. 79.

    Horn D. Barrientos A. (2008 ). Mitochondrial Copper Metabolism and Delivery to Cytochrome C Oxidase. Iubmb Life 60, 421–429.

    Not in our library10.1002/iub.50

  80. 80.

    Hu G. (1998 ). Copper Stimulates Proliferation of Human Endothelial Cells under Culture. J. Biol. Chem. 69, 326–335.

    Not in our library10.1002/(sici)1097-4644(19980601)69:3<326::aid-jcb10>3.0.co;2-a

  81. 81.

    Hu H-L. Ni X-S. Duff-Canning S. Wang X-P. (2016 ). Oxidative Damage of Copper Chloride Overload to the Cultured Rat Astrocytes. Am. J. Translational Res. 8, 1273–1280.

    Not in our library

  82. 82.

    Hu X. Go Y-M. Jones D. P. (2020 ). Omics Integration for Mitochondria Systems Biology. Antioxid. Redox Signaling 32, 853–872.

    Not in our library10.1089/ars.2019.8006

  83. 83.

    Huang X. Pierce L. J. Cobine P. A. Winge D. R. Spangrude G. J. (2009 ). Copper Modulates the Differentiation of Mouse Hematopoietic Progenitor Cells in Culture. Cel Transplant. 18, 887–897.

    Not in our library10.3727/096368909x471152

  84. 84.

    Huang Z. L. Failla M. L. (2000 ). Copper Deficiency Suppresses Effector Activities of Differentiated U937 Cells. J. Nutr. 130, 1536–1542.

    Not in our library10.1093/jn/130.6.1536

  85. 85.

    Huttemann M. Lee I. Samavati L. Yu H. Doan J. W. (2007 ). Regulation of Mitochondrial Oxidative Phosphorylation through Cell Signaling. Biochim. Biophys. Acta 1773, 1701–1720.

    Not in our library10.1016/j.bbamcr.2007.10.001

  86. 86.

    Inesi G. (2016 ). Molecular Features of Copper Binding Proteins Involved in Copper Homeostasis. Iubmb Life 69 (4), 211–217.

    Not in our library10.1002/iub.1590

  87. 87.

    Ishida S. Andreux P. Poitry-Yamate C. Auwerx J. Hanahan D. (2013 ). Bioavailable Copper Modulates Oxidative Phosphorylation and Growth of Tumors. Proc. Natl. Acad. Sci. United States America 110, 19507–19512.

    Not in our library10.1073/pnas.1318431110

  88. 88.

    Itoh S. Kim H. Nakagawa O. Ozumi K. Lessner S. Aoki H. (2008 ). Novel Role of Antioxidant-1 (Atox1) as a Copper-dependent Transcription Factor Involved in Cell Proliferation. J. Biol. Chem. 283, 9157–9167.

    Not in our library10.1074/jbc.m709463200

  89. 89.

    Jaiser S. R. Winston G. P. (2010 ). Copper Deficiency Myelopathy. J. Neurol. 257, 869–881.

    Not in our library10.1007/s00415-010-5511-x

  90. 90.
    Nuclear translocation of Atox1 potentiates activin A-induced cell migration and colony formation in colon cancer. · 2020
    Not checked
  91. 91.

    Jensen E. L. Gonzalez-Ibanez A. M. Mendoza P. Ruiz L. M. Riedel C. A. Simon F. (2019 ). Copper Deficiency-Induced Anemia Is Caused by a Mitochondrial Metabolic Reprograming in Erythropoietic Cells. Metallomics 11, 282–290.

    Not in our library10.1039/c8mt00224j

  92. 92.

    Jett K. A. Leary S. C. (2018 ). Building the Cu A Site of Cytochrome C Oxidase: A Complicated, Redox-dependent Process Driven by a Surprisingly Large Complement of Accessory Proteins. J. Biol. Chem. 293, 4644–4652.

    Not in our library10.1074/jbc.r117.816132

  93. 93.

    Jia X. Chen L. Li J. Su R. Shi D. Tang Z. (2012 ). Effect of Copper Chloride Exposure on the Membrane Potential and Cytosolic Free Calcium in Primary Cultured Chicken Hepatocytes. Biol. Trace Elem. Res. 148, 331–335.

    Not in our library10.1007/s12011-012-9376-y

  94. 94.

    Johnson P. E. Milne D. B. Lykken G. I. (1992 ). Effects of Age and Sex on Copper Absorption, Biological Half-Life, and Status in Humans. Am. J. Clin. Nutr. 56, 917–925.

    Not in our library10.1093/ajcn/56.5.917

  95. 95.

    Kadenbach B. Hüttemann M. (2015 ). The Subunit Composition and Function of Mammalian Cytochrome C Oxidase. Mitochondrion 24, 64–76.

    Not in our library10.1016/j.mito.2015.07.002

  96. 96.

    Kastenhuber E. R. Lowe S. W. (2017 ). Putting P53 in Context. Cell 170, 1062–1078.

    Not in our library10.1016/j.cell.2017.08.028

  97. 97.

    Kim B-E. Nevitt T. Thiele D. J. (2008 ). Mechanisms for Copper Acquisition, Distribution and Regulation. Nat. Chem. Biol. 4, 176–185.

    Not in our library10.1038/nchembio.72

  98. 98.

    Kim B-E. Turski M. L. Nose Y. Casad M. Rockman H. A. Thiele D. J. (2010 ). Cardiac Copper Deficiency Activates a Systemic Signaling Mechanism that Communicates with the Copper Acquisition and Storage Organs. Cel Metab. 11, 353–363.

    Not in our library10.1016/j.cmet.2010.04.003

  99. 99.

    Klöppel C. Suzuki Y. Kojer K. Petrungaro C. Longen S. Fiedler S. (2011 ). Mia40-dependent Oxidation of Cysteines in Domain I of Ccs1 Controls its Distribution between Mitochondria and the Cytosol. Mol. Biol. Cel 22, 3749–3757.

    Not in our library10.1091/mbc.e11-04-0293

  100. 100.

    Koch J. R. Schmid F. X. (2014 ). Mia40 Combines Thiol Oxidase and Disulfide Isomerase Activity to Efficiently Catalyze Oxidative Folding in Mitochondria. J. Mol. Biol. 426, 4087–4098.

    Not in our library10.1016/j.jmb.2014.10.022

  101. 101.

    Kochi N. Tani E. Morimura T. Itagaki T. (1983 ). Immunohistochemical Study of Fibronectin in Human Glioma and Meningioma. Acta Neuropathologica 59, 119–126.

    Not in our library10.1007/bf00691597

  102. 102.

    Koopman W. J. H. Willems P. H. G. M. Smeitink J. A. M. (2012 ). Monogenic Mitochondrial Disorders. New Engl. J. Med. 366, 1132–1141.

    Not in our library10.1056/nejmra1012478

  103. 103.

    Kopp S. J. Klevay L. M. Feliksik J. M. (1983 ). Physiological and Metabolic Characterization of a Cardiomyopathy Induced by Chronic Copper Deficiency. Am. J. Physiol. - Heart Circulatory Physiol. 245, H855–H66.

    Not in our library10.1152/ajpheart.1983.245.5.h855

  104. 104.

    Lamb A. L. Torres A. S. O'Halloran T. V. Rosenzweig A. C. (2000 ). Heterodimer Formation between Superoxide Dismutase and its Copper Chaperone. Biochemistry 39, 14720–14727.

    Not in our library10.1021/bi002207a

  105. 105.

    Larin D. Mekios C. Das K. Ross B. Yang A-S. Gilliam T. C. (1999 ). Characterization of the Interaction between the Wilson and Menkes Disease Proteins and the Cytoplasmic Copper Chaperone. Hah1p. J. Biol. Chem. 274, 28497–28504.

    Not in our library10.1074/jbc.274.40.28497

  106. 106.

    Lassi K. C. Prohaska J. R. (2012 ). Erythrocyte Copper Chaperone for Superoxide Dismutase Is Increased Following Marginal Copper Deficiency in Adult and Postweanling Mice. J. Nutr. 142, 292–297.

    Not in our library10.3945/jn.111.150755

  107. 107.

    Leary S. C. Sasarman F. Nishimura T. Shoubridge E. A. (2009a ). Human SCO2 Is Required for the Synthesis of CO II and as a Thiol-Disulphide Oxidoreductase for SCO1. Hum. Mol. Genet. 18, 2230–2240.

    Not in our library10.1093/hmg/ddp158

  108. 108.

    Leary S. C. Winge D. R. Cobine P. A. (2009b ). “Pulling the Plug” on Cellular Copper: The Role of Mitochondria in Copper export. Biochim. Biophys. Acta-Molecular Cel Res. 1793, 146–153.

    Not in our library10.1016/j.bbamcr.2008.05.002

  109. 109.

    Li Y. (2020 ). Copper Homeostasis: Emerging Target for Cancer Treatment. Iubmb Life 72, 1900–1908.

    Not in our library10.1002/iub.2341

  110. 110.

    Liebes R. Medeiros D. M. (1997 ). Decreased Nuclear Encoded Subunits of Cytochrome C Oxidase and Increased Copper, Zinc-Superoxide Dismutase Activity Are Found in Cardiomyopathic Human Hearts. Int. J. Cardiol. 62, 259–267.

    Not in our library10.1016/s0167-5273(97)00254-4

  111. 111.

    Lill R. Freibert S-A. (2020 ). Mechanisms of Mitochondrial Iron-Sulfur Protein Biogenesis. Annu. Rev. Biochem. 89, 471–499.

    Not in our library10.1146/annurev-biochem-013118-111540

  112. 112.

    Linder M. C. (1991 ). Biochemistry of Copper. Springer US, 525.

    Not in our library

  113. 113.

    Linder M. C. Roboz M. (1986 ). Turnover and Excretion of Copper in Rats as Measured with 67Cu. Am. J. Physiol. - Endocrinol. Metab. 251, E551–E55.

    Not in our library10.1152/ajpendo.1986.251.5.e551

  114. 114.

    Lipsky P. E. (1984 ). Immunosuppression by D-Penicillamine In Vitro. Inhibition of Human T Lymphocyte Proliferation by Copper- or Ceruloplasmin-dependent Generation of Hydrogen Peroxide and protection by Monocytes. J. Clin. Invest. 73, 53–65.

    Not in our library10.1172/jci111207

  115. 115.

    Lipsky P. E. Ziff M. (1980 ). Inhibition of Human Helper T Cell Function In Vitro by D-Penicillamine and CuSO(4). J. Clin. Invest. 65, 1069–1076.

    Not in our library10.1172/jci109759

  116. 116.

    Liu H. Zhang Y. Zheng S. Weng Z. Ma J. Li Y. (2016 ). Detention of Copper by Sulfur Nanoparticles Inhibits the Proliferation of A375 Malignant Melanoma and MCF-7 Breast Cancer Cells. Biochem. Biophysical Res. Commun. 477, 1031–1037.

    Not in our library10.1016/j.bbrc.2016.07.026

  117. 117.

    Loh S. N. (2010 ). The Missing Zinc: P53 Misfolding and Cancer. Metallomics 2, 442–449.

    Not in our library10.1039/c003915b

  118. 118.

    Lowndes S. A. Harris A. L. (2004 ). Copper Chelation as an Antiangiogenic Therapy. Oncol. Res. Featuring Preclinical Clin. Cancer Ther. 14, 529–540.

    Not in our library10.3727/0965040042707952

  119. 119.

    Lowndes S. A. Harris A. L. (2005 ). The Role of Copper in Tumour Angiogenesis. J. Mammary Gland Biol. Neoplasia 10, 299–310.

    Not in our library10.1007/s10911-006-9003-7

  120. 120.

    Luchsinger L. L. de Almeida M. J. Corrigan D. J. Mumau M. Snoeck H-W. (2016 ). Mitofusin 2 Maintains Hematopoietic Stem Cells with Extensive Lymphoid Potential. Nature 529, 528–531.

    Not in our library10.1038/nature16500

  121. 121.

    Maryanovich M. Gross A. (2013 ). A ROS Rheostat for Cell Fate Regulation. Trends Cell Biology 23, 129–134.

    Not in our library10.1016/j.tcb.2012.09.007

  122. 122.

    Matsubara T. Hirohata K. (1988 ). Suppression of Human Fibroblast Proliferation by D-Penicillamine and Copper Sulfate In Vitro. Arthritis Rheum. 31, 964–972.

    Not in our library10.1002/art.1780310804

  123. 123.

    McCord J. M. Fridovich I. (1969 ). Superoxide Dismutase: AN ENZYMIC FUNCTION for ERYTHROCUPREIN (HEMOCUPREIN). J. Biol. Chem. 244, 6049–6055.

    Not in our library10.1016/s0021-9258(18)63504-5

  124. 124.

    Medeiros D. M. Jennings D. (2002 ). Role of Copper in Mitochondrial Biogenesis via Interaction with ATP Synthase and Cytochrome C Oxidase. J. Bioenerg. Biomembr 34, 389–395.

    Not in our library10.1023/a:1021206220851

  125. 125.

    Medeiros D. M. Shiry L. Samelman T. (1997 ). Cardiac Nuclear Encoded Cytochrome C Oxidase Subunits Are Decreased with Copper Restriction but Not Iron Restriction: Gene Expression, Protein Synthesis and Heat Shock Protein Aspects. Comp. Biochem. Physiol. A. Physiol. 117, 77–87.

    Not in our library10.1016/s0300-9629(96)00365-9

  126. 126.
    The Cu, Zn Superoxide Dismutase: Not Only a Dismutase Enzyme · 2016
    No notice
  127. 127.

    Morgada M. N. Abriata L. A. Cefaro C. Gajda K. Banci L. Vila A. J. (2015 ). Loop Recognition and Copper-Mediated Disulfide Reduction Underpin Metal Site Assembly of Cu(A) in Human Cytochrome Oxidase. Proc. Natl. Acad. Sci. United States America 112, 11771–11776.

    Not in our library10.1073/pnas.1505056112

  128. 128.
    CTR1 silencing inhibits angiogenesis by limiting copper entry into endothelial cells. · 2013
    Not checked
  129. 129.

    Oe S. Miyagawa K. Honma Y. Harada M. (2016 ). Copper Induces Hepatocyte Injury Due to the Endoplasmic Reticulum Stress in Cultured Cells and Patients with Wilson Disease. Exp. Cel Res. 347, 192–200.

    Not in our library10.1016/j.yexcr.2016.08.003

  130. 130.

    Oliveri V. Lanza V. Milardi D. Viale M. Maric I. Sgarlata C. (2017 ). Amino- and Chloro-8-Hydroxyquinolines and Their Copper Complexes as Proteasome Inhibitors and Antiproliferative Agents. Metallomics 9, 1439–1446.

    Not in our library10.1039/c7mt00156h

  131. 131.

    Owen C. A. J. (1971 ). Metabolism of Copper 67 by the Copper-Deficient Rat. Am. J. Physiology-Legacy Content 221, 1722–1727.

    Not in our library10.1152/ajplegacy.1971.221.6.1722

  132. 132.

    Pacheu-Grau D. Wasilewski M. Oeljeklaus S. Gibhardt C. S. Aich A. Chudenkova M. (2020 ). COA6 Facilitates Cytochrome C Oxidase Biogenesis as Thiol-Reductase for Copper Metallochaperones in Mitochondria. J. Mol. Biol. 432, 2067–2079.

    Not in our library10.1016/j.jmb.2020.01.036

  133. 133.

    Pan Q. Kleer C. G. van Golen K. L. Irani J. Bottema K. M. Bias C. (2002 ). Copper Deficiency Induced by Tetrathiomolybdate Suppresses Tumor Growth and Angiogenesis. Cancer Res. 62, 4854–4859.

    Not in our library

  134. 134.

    Parke A. Bhattacherjee P. Palmer R. M. Lazarus N. R. (1988 ). Characterization and Quantification of Copper Sulfate-Induced Vascularization of the Rabbit Cornea. Am. J. Pathol. 130, 173–178.

    Not in our library

  135. 135.

    Pass H. I. Brewer G. J. Dick R. Carbone M. Merajver S. (2008 ). A Phase II Trial of Tetrathiomolybdate after Surgery for Malignant Mesothelioma: Final Results. Ann. Thorac. Surg. 86, 383–390.

    Not in our library10.1016/j.athoracsur.2008.03.016

  136. 136.

    Peled T. Glukhman E. Hasson N. Adi S. Assor H. Yudin D. K. (2005 ). Chelatable Cellular Copper Modulates Differentiation and Self-Renewal of Cord Blood–Derived Hematopoietic Progenitor Cells. Exp. Hematol. 33, 1092–1100.

    Not in our library10.1016/j.exphem.2005.06.015

  137. 137.

    Peled T. Landau E. Prus E. Treves A. J. Fibach E. (2002 ). Cellular Copper Content Modulates Differentiation and Self‐renewal in Cultures of Cord Blood‐derived CD34+ Cells. Br. J. Haematol. 116, 655–661.

    Not in our library10.1046/j.0007-1048.2001.03316.x

  138. 138.

    Pettenuzzo N. Brustolin L. Coltri E. Gambalunga A. Chiara F. Trevisan A. (2019 ). CuII and AuIII Complexes with Glycoconjugated Dithiocarbamato Ligands for Potential Applications in Targeted Chemotherapy. ChemMedChem 14, 1162–1172.

    Not in our library10.1002/cmdc.201900226

  139. 139.

    Piccoli C. Agriesti F. Scrima R. Falzetti F. Di Ianni M. Capitanio N. (2013 ). To Breathe or Not to Breathe: the Haematopoietic Stem/progenitor Cells Dilemma. Br. J. Pharmacol. 169, 1652–1671.

    Not in our library10.1111/bph.12253

  140. 140.

    Piccoli C. Ria R. Scrima R. Cela O. D'Aprile A. Boffoli D. (2005 ). Characterization of Mitochondrial and Extra-mitochondrial Oxygen Consuming Reactions in Human Hematopoietic Stem Cells: NOVEL EVIDENCE of the OCCURRENCE of NAD(P)H OXIDASE ACTIVITY *. J. Biol. Chem. 280, 26467–26476.

    Not in our library10.1074/jbc.m500047200

  141. 141.

    Piccoli C. Scrima R. Boffoli D. Capitanio N. (2006 ). Control by Cytochrome C Oxidase of the Cellular Oxidative Phosphorylation System Depends on the Mitochondrial Energy State. Biochem. J. 396, 573–583.

    Not in our library10.1042/bj20060077

  142. 142.

    Porcu C. Antonucci L. Barbaro B. Illi B. Nasi S. Martini M. (2018 ). Copper/MYC/CTR1 Interplay: a Dangerous Relationship in Hepatocellular Carcinoma. Oncotarget 9, 9325–9343.

    Not in our library10.18632/oncotarget.24282

  143. 143.

    Puig S. Thiele D. J. (2002 ). Molecular Mechanisms of Copper Uptake and Distribution. Curr. Opin. Chem. Biol. 6, 171–180.

    Not in our library10.1016/s1367-5931(02)00298-3

  144. 144.

    Qin Z. Gongora M. C. Ozumi K. Itoh S. Akram K. Ushio-Fukai M. (2008 ). Role of Menkes ATPase in Angiotensin II-Induced Hypertension. A Key Modulator Extracellular Superoxide Dismutase Funct. 52, 945–951.

    Not in our library10.1161/hypertensionaha.108.116467

  145. 145.

    Qiu L. Ding X. Zhang Z. Kang Y. J. (2012 ). Copper Is Required for Cobalt-Induced Transcriptional Activity of Hypoxia-Inducible Factor-1. J. Pharmacol. Exp. Ther. 342, 561–567.

    Not in our library10.1124/jpet.112.194662

  146. 146.

    Redman B. G. Esper P. Pan Q. Dunn R. L. Hussain H. K. Chenevert T. (2003 ). Phase II Trial of Tetrathiomolybdate in Patients with Advanced Kidney Cancer. Clin. Cancer Res. 9, 1666–1672.

    Not in our library

  147. 147.

    Rhee S. G. Yang K-S. Kang S. W. Woo H. A. Chang T-S. (2005 ). Controlled Elimination of Intracellular H2O2: Regulation of Peroxiredoxin, Catalase, and Glutathione Peroxidase via Post-translational Modification. Antioxid. Redox Signaling 7, 619–626.

    Not in our library10.1089/ars.2005.7.619

  148. 148.

    Robinson N. J. Winge D. R. (2010 ). Copper Metallochaperones. Annu. Rev. Biochem. 79, 537–562.

    Not in our library10.1146/annurev-biochem-030409-143539

  149. 149.

    Rodríguez J. Ríos S. González M. (2002 ). Modulation of the Proliferation and Differentiation of Human Mesenchymal Stem Cells by Copper. J. Cel Biochem 85, 92–100.

    Not in our library10.1002/jcb.10111

  150. 150.

    Rossi L. Lippe G. Marchese E. De Martino A. Mavelli I. Rotilio G. (1998 ). Decrease of Cytochrome C Oxidase Protein in Heart Mitochondria of Copper-Deficient Rats. Biometals 11, 207–212.

    Not in our library10.1023/a:1009274131473

  151. 151.

    Rossi L. Lombardo M. F. Ciriolo M. R. Rotilio G. (2004 ). Mitochondrial Dysfunction in Neurodegenerative Diseases Associated with Copper Imbalance. Neurochem. Res. 29, 493–504.

    Not in our library10.1023/b:nere.0000014820.99232.8a

  152. 152.

    Ruiz L. M. Jensen E. L. Bustos R. I. Argüelloa G. Gutierrez-Garcia R. González M. (2014 ). Adaptive Responses of Mitochondria to Mild Copper Deprivation Involve Changes in Morphology, OXPHOS Remodeling and Bioenergetics. J. Cell Physiol. 229, 607–619.

    Not in our library10.1002/jcp.24484

  153. 153.

    Ruiz L. M. Jensen E. L. Rossel Y. Puas G. I. Gonzalez-Ibanez A. M. Bustos R. I. (2016 ). Non-cytotoxic Copper Overload Boosts Mitochondrial Energy Metabolism to Modulate Cell Proliferation and Differentiation in the Human Erythroleukemic Cell Line K562. Mitochondrion 29, 18–30.

    Not in our library10.1016/j.mito.2016.04.005

  154. 154.

    Ruiz-Azuara L. Bravo-Gomez M. E. (2010 ). Copper Compounds in Cancer Chemotherapy. Curr. Med. Chem. 17, 3606–3615.

    Not in our library10.2174/092986710793213751

  155. 155.

    Scanni A. Licciardello L. Trovato M. Tomirotti M. Biraghi M. (1977 ). Serum Copper and Ceruloplasmin Levels in Patients with Neoplasias Localized in the Stomach, Large Intestine or Lung. Tumori 63, 175–180.

    Not in our library10.1177/030089167706300208

  156. 156.

    Schagger H. Pfeiffer K. (2000 ). Supercomplexes in the Respiratory Chains of Yeast and Mammalian Mitochondria. EMBO J. 19, 1777–1783.

    Not in our library10.1093/emboj/19.8.1777

  157. 157.

    Schulze A. Harris A. L. (2012 ). How Cancer Metabolism Is Tuned for Proliferation and Vulnerable to Disruption. Nature 491, 364.

    Not in our library10.1038/nature11706

  158. 158.

    Shoubridge E. A. (2012 ). Supersizing the Mitochondrial Respiratory Chain. Cel Metab. 15, 271–272.

    Not in our library10.1016/j.cmet.2012.02.009

  159. 159.
    COA6 Is Structurally Tuned to Function as a Thiol-Disulfide Oxidoreductase in Copper Delivery to Mitochondrial Cytochrome c Oxidase · 2019
    Not checked
  160. 160.

    Soncin F. Guitton J-D. Cartwright T. Badet J. (1997 ). Interaction of Human Angiogenin with Copper Modulates Angiogenin Binding to Endothelial Cells. Biochem. Biophysical Res. Commun. 236, 604–610.

    Not in our library10.1006/bbrc.1997.7018

  161. 161.

    Stroud D. A. Maher M. J. Lindau C. Vögtle F-N. Frazier A. E. Surgenor E. (2015 ). COA6 Is a Mitochondrial Complex IV Assembly Factor Critical for Biogenesis of mtDNA-Encoded COX2. Hum. Mol. Genet. 24, 5404–5415.

    Not in our library10.1093/hmg/ddv265

  162. 162.

    Su R. Wang R. Guo S. Cao H. Pan J. Li C. (2011 ). In Vitro effect of Copper Chloride Exposure on Reactive Oxygen Species Generation and Respiratory Chain Complex Activities of Mitochondria Isolated from Broiler Liver. Biol. Trace Elem. Res. 144, 668–677.

    Not in our library10.1007/s12011-011-9039-4

  163. 163.

    Suska F. Esposito M. Gretzer C. Källtorp M. Tengvall P. Thomsen P. (2003 ). IL-1α, IL-1β and TNF-α Secretion during In Vivo/Ex Vivo Cellular Interactions with Titanium and Copper. Biomaterials 24, 461–468.

    Not in our library10.1016/s0142-9612(02)00359-9

  164. 164.

    Takubo K. Goda N. Yamada W. Iriuchishima H. Ikeda E. Kubota Y. (2010 ). Regulation of the HIF-1 Alpha; Level Is Essential for Hematopoietic Stem Cells. Cell Stem Cell 7, 391–402.

    Not in our library10.1016/j.stem.2010.06.020

  165. 165.

    Teknos T. N. Islam M. Arenberg D. A. Pan Q. Carskadon S. L. Abarbanell A. M. (2005 ). The Effect of Tetrathiomolybdate on Cytokine Expression, Angiogenesis, and Tumor Growth in Squamous Cell Carcinoma of the Head and Neck. Arch. Otolaryngology–Head Neck Surg. 131, 204–211.

    Not in our library10.1001/archotol.131.3.204

  166. 166.

    Tisato F. Marzano C. Porchia M. Pellei M. Santini C. (2010 ). Copper in Diseases and Treatments, and Copper-Based Anticancer Strategies. Med. Res. Rev. 30, 708–749.

    Not in our library10.1002/med.20174

  167. 167.

    Tsang T. Posimo J. M. Gudiel A. A. Cicchini M. Feldser D. M. Brady D. C. (2020 ). Copper Is an Essential Regulator of the Autophagic Kinases ULK1/2 to Drive Lung Adenocarcinoma. Nat. Cel Biol. 22, 412–424.

    Not in our library10.1038/s41556-020-0481-4

  168. 168.

    Turnlund J. R. Keyes W. R. Peiffer G. L. Scott K. C. (1998 ). Copper Absorption, Excretion, and Retention by Young Men Consuming Low Dietary Copper Determined by Using the Stable Isotope 65Cu. Am. J. Clin. Nutr. 67, 1219–1225.

    Not in our library10.1093/ajcn/67.6.1219

  169. 169.

    Turski M. L. Thiele D. J. (2009 ). New Roles for Copper Metabolism in Cell Proliferation, Signaling, and Disease. J. Biol. Chem. 284, 717–721.

    Not in our library10.1074/jbc.r800055200

  170. 170.

    Ungar-Waron H. Gluckman A. Spira E. Waron M. Trainin Ze. (1978 ). Ceruloplasmin as a Marker of Neoplastic Activity in Rabbits Bearing the VX-2 Carcinoma. Cancer Res. 38, 1296–1299.

    Not in our library

  171. 171.

    Vallières C. Holland S. L. Avery S. V. (2017 ). Mitochondrial Ferredoxin Determines Vulnerability of Cells to Copper Excess. Cel Chem. Biol. 24, 1228–1237.

    Not in our library10.1016/j.chembiol.2017.08.005

  172. 172.

    Vest K. E. Leary S. C. Winge D. R. Cobine P. A. (2013 ). Copper Import into the Mitochondrial Matrix in Saccharomyces cerevisiae Is Mediated by Pic2, a Mitochondrial Carrier Family Protein. J. Biol. Chem. 288, 23884–23892.

    Not in our library10.1074/jbc.m113.470674

  173. 173.

    Vest K. E. Wang J. Gammon M. G. Maynard M. K. White O. L. Cobine J. A. (2016 ). Overlap of Copper and Iron Uptake Systems in Mitochondria in Saccharomyces cerevisiae. Open Biol. 6, 150223.

    Not in our library10.1098/rsob.150223

  174. 174.

    Voli F. Valli E. Lerra L. Kimpton K. Saletta F. Giorgi F. (2020 ). Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion. Cancer Res. 80, 4129–4144.

    Not in our library10.1158/0008-5472.can-20-0471

  175. 175.

    Vozza A. Parisi G. De Leonardis F. Lasorsa F. M. Castegna A. Amorese D. (2014 ). UCP2 Transports C4 Metabolites Out of Mitochondria, Regulating Glucose and Glutamine Oxidation. Proc. Natl. Acad. Sci. United States America 111, 960–965.

    Not in our library10.1073/pnas.1317400111

  176. 176.

    Wagner K. U. Claudio E. Rucker E. B. Riedlinger G. Broussard C. Schwartzberg P. L. (2000 ). Conditional Deletion of the Bcl-X Gene from Erythroid Cells Results in Hemolytic Anemia and Profound Splenomegaly. Development 127, 4949–4958.

    Not in our library10.1242/dev.127.22.4949

  177. 177.

    Wakabayashi T. Asano M. Kurono C. (1975 ). Mechanism of the Formation of Mega Mitochondria Induced by Copper Chelating Agents Part 1 on the Formation Process of Mega Mitochondria in Cuprizone Treated Mouse Liver. Acta Pathol. Jpn. 25, 15–38.

    Not in our library10.1111/j.1440-1827.1975.tb00147.x

  178. 178.

    Wakabayashi T. (2002 ). Megamitochondria Formation - Physiology and Pathology. J. Cel Mol Med 6, 497–537.

    Not in our library10.1111/j.1582-4934.2002.tb00452.x

  179. 179.

    Wanet A. Arnould T. Najimi M. Renard P. (2015 ). Connecting Mitochondria, Metabolism, and Stem Cell Fate. Stem Cell Dev. 24, 1957–1971.

    Not in our library10.1089/scd.2015.0117

  180. 180.

    Wang J. Chen J. Tang Z. Li Y. Hu L. Pan J. (2016 ). The Effects of Copper on Brain Microvascular Endothelial Cells and Claudin via Apoptosis and Oxidative Stress. Biol. Trace Elem. Res. 174, 132–141.

    Not in our library10.1007/s12011-016-0685-4

  181. 181.

    Wang J. Luo C. Shan C. You Q. Lu J. Elf S. (2015 ). Inhibition of Human Copper Trafficking by a Small Molecule Significantly Attenuates Cancer Cell Proliferation. Nat. Chem. 7, 968–979.

    Not in our library10.1038/nchem.2381

  182. 182.

    Wang Y. Branicky R. Noë A. Hekimi S. (2018 ). Superoxide Dismutases: Dual Roles in Controlling ROS Damage and Regulating ROS Signaling. J. Cel. Biol. 217, 1915–1928.

    Not in our library10.1083/jcb.201708007

  183. 183.

    Xu W. Barrientos T. Andrews Nancy C. (2013a ). Iron and Copper in Mitochondrial Diseases. Cel Metab. 17, 319–328.

    Not in our library10.1016/j.cmet.2013.02.004

  184. 184.

    Xu X. Duan S. Yi F. Ocampo A. Liu G-H. Izpisua Belmonte Juan C. (2013b ). Mitochondrial Regulation in Pluripotent Stem Cells. Cel Metab. 18, 325–332.

    Not in our library10.1016/j.cmet.2013.06.005

  185. 185.

    Yonashiro R. Sugiura A. Miyachi M. Fukuda T. Matsushita N. Inatome R. (2009 ). Mitochondrial Ubiquitin Ligase MITOL Ubiquitinates Mutant SOD1 and Attenuates Mutant SOD1-Induced Reactive Oxygen Species Generation. Mol. Biol. Cel 20, 4524–4530.

    Not in our library10.1091/mbc.e09-02-0112

  186. 186.

    Yoon Y. Krueger E. W. Oswald B. J. McNiven M. A. (2003 ). The Mitochondrial Protein hFis1 Regulates Mitochondrial Fission in Mammalian Cells through an Interaction with the Dynamin-like Protein DLP1. Mol. Cell Biol. 23, 5409–5420.

    Not in our library10.1128/mcb.23.15.5409-5420.2003

  187. 187.

    Yoshida D. Ikeda Y. Nakazawa S. (1995 ). Suppression Of Tumor Growth In Experimental 9L Gliosarcoma Model By Copper Depletion. Neurologia medico-chirurgica 35, 133–135.

    Not in our library10.2176/nmc.35.133

  188. 188.

    Yoshii J. Yoshiji H. Kuriyama S. Ikenaka Y. Noguchi R. Okuda H. (2001 ). The Copper-Chelating Agent, Trientine, Suppresses Tumor Development and Angiogenesis in the Murine Hepatocellular Carcinoma Cells. Int. J. Cancer 94, 768–773.

    Not in our library10.1002/ijc.1537

  189. 189.

    Zelko I. N. Mariani T. J. Folz R. J. (2002 ). Superoxide Dismutase Multigene Family: a Comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) Gene Structures, Evolution, and Expression. Free Radic. Biol. Med. 33, 337–349.

    Not in our library10.1016/s0891-5849(02)00905-x

  190. 190.

    Zeng H. Saari J. T. Johnson W. T. (2007 ). Copper Deficiency Decreases Complex IV but Not Complex I, II, III, or V in the Mitochondrial Respiratory Chain in Rat Heart. J. Nutr. 137, 14–18.

    Not in our library10.1093/jn/137.1.14

  191. 191.

    Zhang J. Khvorostov I. Hong J. Oktay Y. Vergnes L. Nuebel E. (2011 ). UCP2 Regulates Energy Metabolism and Differentiation Potential of Human Pluripotent Stem Cells. EMBO J. 30, 4860–4873.

    Not in our library10.1038/emboj.2011.401

  192. 192.

    Zhang W. Chen C. Shi H. Yang M. Liu Y. Ji P. (2016 ). Curcumin Is a Biologically Active Copper Chelator with Antitumor Activity. Phytomedicine 23, 1–8.

    Not in our library10.1016/j.phymed.2015.11.005

  193. 193.

    Zidar B. L. Shadduck R. K. Zeigler Z. Winkelstein A. (1977 ). Observations on the Anemia and Neutropenia of Human Copper Deficiency. Am. J. Hematol. 3, 177–185.

    Not in our library10.1002/ajh.2830030209

  194. 194.

    Zuo J. Bi C. Fan Y. Buac D. Nardon C. Daniel K. G. (2013 ). Cellular and Computational Studies of Proteasome Inhibition and Apoptosis Induction in Human Cancer Cells by Amino Acid Schiff Base-Copper Complexes. J. Inorg. Biochem. 118, 83–93.

    Not in our library10.1016/j.jinorgbio.2012.10.006

Cited by papers we hold 8

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.